For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260429:nRSc2888Ca&default-theme=true
RNS Number : 2888C Haleon PLC 29 April 2026
Haleon plc: 2026 Q1 Trading Statement
29 April 2026: Haleon plc (the "Company" or "Haleon") today announces its Q1
trading statement for the year ending 31 December 2026 is available
at: http://www.rns-pdf.londonstockexchange.com/rns/2888C_1-2026-4-28.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/2888C_1-2026-4-28.pdf) .
The Q1 trading statement will also be available on the Haleon website
www.haleon.com/investors (http://www.haleon.com/investors) , and has been
submitted in full unedited text to the Financial Conduct Authority's National
Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Brian McNamara,
Chief Executive Officer, and Dawn Allen, Chief Financial Officer at 9:00am BST
(10:00am CEST) on 29 April 2026, which can be accessed at
www.haleon.com/investors/ (http://www.haleon.com/investors/) .
For analysts and shareholders wishing to ask questions on the Q&A call,
please use the dial-in details below which will have a Q&A facility:
UK: +44 (0) 808 189 0158
US: +1 855 979 6654
All other: +44 (0) 203 936 2999
Passcode: 975813
An archived webcast of the Q&A call will be available later on the day of
the results and can be accessed at www.haleon.com/investors
(http://www.haleon.com/investors) .
Amanda Mellor
Company Secretary
Enquiries
Investors Media
Jo Russell +44 7787 392441 Zoë Bird +44 7736 746167
Rakesh Patel +44 7552 484646 Victoria Durman +44 7894 505730
Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com) Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.
For more information, please visit www.haleon.com (http://www.haleon.com/)
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TSTAKFBBOBKDAQB
Copyright 2019 Regulatory News Service, all rights reserved